FDA Approves Landmark Pancreatic Cancer Drug, Daraxonrasib (Rasonque), Doubling Survival Rates

The U.S. Food and Drug Administration has approved daraxonrasib, marketed as Rasonque, a novel oral therapy for advanced pancreatic cancer. This first-of-its-kind pill targets a mutated protein driving tumor growth in over 90% of cases, with clinical trials showing it nearly doubles patient survival time.